Keeping perspective on AI’s role in biotech

Enthusiasm for AI has spilled into biotech, with numerous accounts of how the advanced technology will revolutionize the sector. But drug development is multifaceted, and some stages of the process, such as regulatory filings and clinical testing, may see limited benefit from AI in the near term. In our view, investors should keep perspective and stay focused on what matters most to the value of biotech companies: approved products backed by clinical data.